Tuesday, September 26, 2023


Biotechnology News Magazine

Zeon Corporation Reaches An Agreement to Acquire Aurora Microplates

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Zeon Corporation, a world leader in specialty elastomers, polymers, and specialty chemicals, has reached agreement to acquire Aurora Microplates, a leading manufacturer and supplier of high-performance microplates. The official announcement was made in Tokyo today.  The acquisition is expected to be completed by February 28, 2022.

“We are very excited to enter the high-value high-performance microplate market. For more than 20 years we have supplied Aurora Microplates with polymer and film material for its microplates, and we are pleased to be able to enter the drug discovery research markets with a highly respected and knowledgeable partner” said Kimiaki Tanaka, President, and CEO at Zeon Corporation.

The Aurora Microplates business fits into Zeon Corporation’s strategy to deliver the best material and products to enable users involved in research and diagnostics to improve human health. Through Aurora Microplates, Zeon will support front-line scientists in their quest to better understand the subtle clues involved in animal and human health.

“We are thrilled to be working in complete synergy with Zeon, our resin and film supplier since Aurora was born more than 20 years ago” said Charles Powell, Managing Partner at Aurora Microplates, “this combination of raw material supplier and Microplate Manufacturer is unique in the marketplace- and will provide our current and future microplates users piece of mind with respect to microplate supply for their critical research needs.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine